[Combination effects of CDDP, ACR and HCFU on progressive urothelial tumors].
Nine patients with progressive urothelial tumors treated with combination chemotherapy were evaluated. The median age of the patients was fifty-four; 6 men and 3 women; 7 of the tumors were of the renal pelvis and/or ureter and at stage C or D at the time of initial chemotherapy. Another of the tumors was triple cancer (bladder, prostate, sigmoid) and the remaining case was of bladder cancer. The stage of the two bladders cancers was T4. All patients were treated with CDDP (cis-platinum), ACR (aclarubicin hydrochloride) and HCFU (carmoful) and given from one to 3 courses repeated at three-week intervals (mean 2.3 courses). Seven patients were evaluable while two had no evaluable lesions. The response with this chemotherapy was 2 cases of PR (28.5%), 4 cases of NC and one case of PD. No severe toxicities such as nephrotoxicity or cardiotoxicity, were revealed with this combination chemotherapy.
D015250:Aclarubicin; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D004334:Drug Administration Schedule; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000031:analogs & derivatives; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy; D007682:Kidney Pelvis; D008297:Male; D008875:Middle Aged; D009279:Naphthacenes / Q000008:administration & dosage; D014516:Ureteral Neoplasms / Q000188:drug therapy; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy; D014571:Urologic Neoplasms / Q000188:drug therapy*
D009279:Naphthacenes; D015250:Aclarubicin; C017367:carmofur; D002945:Cisplatin; D005472:Fluorouracil